Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
255 participants
INTERVENTIONAL
2023-11-28
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Study of DF1001 in Patients with Advanced Solid Tumors
NCT04143711
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
NCT05205109
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
NCT04157517
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
NCT06234397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Monotherapy Dose Escalation
Patients will receive DF6215 monotherapy, with dose levels escalated to determine the MTD of DF6215 monotherapy.
DF6215
Immunotherapy (cytokine) targeting effector cells.
Combination Therapy Dose Escalation
Patients will receive DF6215 in combination with pembrolizumab to determine the MTD of DF6215 in combination with pembrolizumab.
DF6215
Immunotherapy (cytokine) targeting effector cells.
pembrolizumab
Anti-PD-1 immunotherapy agent
KEYTRUDA®
Anti-PD-1 immunotherapy agent
Monotherapy Dose Enrichment
Patients with advanced melanoma after prior anti-PD-1 treatment will receive DF6215 monotherapy at two different dose levels to further characterize the doses selected during the Dose Escalation (monotherapy) part.
DF6215
Immunotherapy (cytokine) targeting effector cells.
Monotherapy Expansion of DF6215 in Advanced Melanoma
Patients with advanced melanoma after prior anti-PD-1 will receive DF6215 monotherapy at the recommended efficacy expansion dose to evaluate the clinical activity of DF6215 in monotherapy.
DF6215
Immunotherapy (cytokine) targeting effector cells.
Combination Expansion of DF6215 and pembrolizumab in PROC
Patients with platinum-resistant ovarian cancer (PROC) will receive DF6215 in combination with pembrolizumab at the recommended efficacy expansion dose to evaluate the clinical activity of DF6215 in combination with pembrolizumab.
DF6215
Immunotherapy (cytokine) targeting effector cells.
pembrolizumab
Anti-PD-1 immunotherapy agent
KEYTRUDA®
Anti-PD-1 immunotherapy agent
Combination Expansion of DF6215 and pembrolizumab in Advanced Melanoma
Patients with advanced melanoma after prior anti-PD-1 therapy will receive DF6215 in combination with pembrolizumab at the recommended combination efficacy expansion dose to evaluate the clinical activity of DF6215 in combination with pembrolizumab.
DF6215
Immunotherapy (cytokine) targeting effector cells.
pembrolizumab
Anti-PD-1 immunotherapy agent
KEYTRUDA®
Anti-PD-1 immunotherapy agent
Monotherapy Expansion of DF6215 in Multiple Tumor Types (Basket)
Patients with multiple tumor types will receive DF6215 monotherapy at the recommended efficacy expansion dose to evaluate the clinical activity of DF6215 in monotherapy.
DF6215
Immunotherapy (cytokine) targeting effector cells.
Combination Expansion of DF6215 and pembrolizumab in Multiple Tumor Types
Patients with multiple tumor types will receive DF6215 in combination with pembrolizumab at the recommended combination efficacy expansion dose to evaluate the clinical activity of DF6215 in combination with pembrolizumab.
DF6215
Immunotherapy (cytokine) targeting effector cells.
pembrolizumab
Anti-PD-1 immunotherapy agent
KEYTRUDA®
Anti-PD-1 immunotherapy agent
DF6215 Monotherapy Safety/PK/PD
Expansion cohorts of DF6215 in multiple dose levels after evaluation for safety in the DF6215 Dose Escalation arm. Additional Pharmacokinetic (PK) and Pharmacodynamic (PD) samples included in this arm.
DF6215
Immunotherapy (cytokine) targeting effector cells.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DF6215
Immunotherapy (cytokine) targeting effector cells.
pembrolizumab
Anti-PD-1 immunotherapy agent
KEYTRUDA®
Anti-PD-1 immunotherapy agent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* An estimated life expectancy of ≥ 3 months.
* Adequate hematological function.
* Normal pulmonary function.
* Adequate hepatic function.
* Adequate renal function.
* Effective Contraception.
Exclusion Criteria
* Patients receiving any of the following concurrent anticancer treatments or investigational drugs within 28 days before the start of the study drug(s), or within 5 half-lives of the previous therapeutic agent (if known), whichever is shorter:
* Cytoreductive therapy
* Radiotherapy (except for palliative bone-directed radiotherapy)
* Note: ≤ 2 weeks of palliative radiotherapy for non-CNS disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study drug.
* Immune therapy
* Cytokine therapy (except for erythropoietin)
* Major surgery (excluding prior diagnostic biopsy)
* Concurrent systemic therapy with steroids or other immunosuppressive agents.
* Note that short-term administration of systemic steroids (eg, for allergic reactions or the management of irAEs) and physiologic dose steroids (≤ 10 mg prednisone, or equivalent) for those with treated brain metastases are allowed. Patients receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug(s) will be excluded.
* Bisphosphonate or denosumab initiated within 14 days of the first dose of study drug(s)
* Previous malignant disease, other than the target malignancies to be investigated in this study, within the last 3 years. Exceptions (eg, basal or squamous cell carcinoma of the skin, low grade prostate cancer \[Gleason score ≤ 6 and must be Stage I or II\], or cervical carcinoma in situ) may be considered on a case-by-case basis, in consultation with the Medical Monitor.
* Any of the following cardiac abnormalities:
* A clinically relevant abnormality on the electrocardiogram (ECG)
* Clinically relevant coronary artery disease (CAD) or uncontrolled congestive heart failure
* Medically uncontrolled angina pectoris
* An implantable pacemaker or automatic implantable cardioverter-defibrillator
* A history of risk factors for ventricular tachycardia, torsades de pointes, fainting, unexplained loss of consciousness, or convulsions
* A history of heart failure, congestive heart failure, cardiomyopathy, uncontrolled hypokalemia, hypomagnesemia, or hypoglycemia; any evidence of conduction abnormality (eg, increased QRS complex)
* Congenital long QT syndrome or a prolonged QTc mean on screening ECG
* QTc \> 470 msec for women and \> 450 msec for men
* History of myocardial infarction within 6 months before the first dose of study drug(s)
* Received sotalol within 10 days of the first dose of study drug(s), or received a medication known to prolong the ECG QT interval within 14 days of the first dose of study drug(s)
* A heart rate of \< 50 or \> 100 bpm at rest on screening ECG
* Patients aged more than 50 years must have a normal cardiac stress test.
* Patients with history of CAD must have a normal stress test (eg, thallium or technetium-99m sestamibi) and be cleared to participate in the study.
* History of ocular/uveal melanoma or mucosal melanoma.
* Primary tumor site of nasopharynx (any histology).
* Patients with brain metastases are excluded, unless all of the following criteria are met:
* CNS lesions are asymptomatic and previously treated
* Patient does not require ongoing daily steroid treatment for replacement for adrenal insufficiency (except ≤ 10 mg prednisone \[or equivalent\]) for at least 14 days before the first dose of study drug
* Imaging demonstrates stable disease 28 days after last treatment
* Receipt of any organ transplant, including autologous or allogeneic stem-cell transplantation.
* Patients must not have received aldesleukin or any other experimental IL-2 based drug, including intralesional administration.
* Significant acute or chronic hepatitis B virus (HBV), hepatitis C virus (HCV) infection during the screening window, as well as historic positive for human immunodeficiency virus (HIV) or clinically significant active infections that render the patient ineligible for study treatment as determined by the treating investigator.
* Patients with known HIV infection are excluded unless they meet the following criteria:
* Must have CD4+ T-cell (CD4+) counts ≥ 350 cells/μL at the time of screening, and
* Must have no history of AIDS-related opportunistic infections of HIV-associated conditions such as Kaposi sarcoma or multicentric Castleman's disease, and
* Patients on antiretroviral therapy (ART) must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening and agree to continue ART throughout the study
* Preexisting autoimmune disease (except vitiligo) needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years, or clinically relevant immunodeficiencies (eg, dysgammaglobulinemia or congenital immunodeficiencies). Patients with a history of immune related endocrinopathies (eg, hypothyroidism, hyperthyroidism, and type 1 diabetes mellitus) that are stable on hormone replacement therapy are eligible for this study.
* Patients with a known medical history of keratitis, ulcerative keratitis, or corneal perforation.
* Patients with known history of neurologic conditions, cerebrovascular accident, or seizures.
* Known severe hypersensitivity reactions to mAbs (≥ Grade 3 as defined by NCI-CTCAE v5.0), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partly controlled asthma).
* Persisting toxicity related to a prior therapeutic agent \> Grade 1 as defined by NCI CTCAE v5.0 (however, ≤ Grade 2 alopecia, ≤ Grade 2 endocrinopathies, and ≤ Grade 2 sensory neuropathy are acceptable).
* Patients in certain cohorts with prior anti-PD-1 and anti-PD-L1 treatment are eligible for the study, unless they have experienced any of the following:
* Grade 3 or 4 treatment-related toxicity during an anti-PD-1 or anti-PD-L1 treatment (excluding Grade 3 or 4 immune-related endocrinopathies adequately controlled with hormone replacement therapy).
* Grade 2 treatment-related toxicity that impacted either the lungs, the nervous system, or the cardiac system, during an anti-PD-1 or anti-PD-L1 treatment (patients with a history of Grade 2 peripheral neuropathy, or paresthesia, not related to anti-PD-1 or anti-PD-L1 treatments are eligible).
* For combination basket cohorts: received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
* For combination basket cohorts: received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.
* Known alcohol or drug abuse.
* Severe dyspnea at rest due to complications of advanced malignancy.
* Requiring supplementary oxygen therapy.
* All other significant diseases (eg, inflammatory bowel disease) which, in the opinion of the Investigator, might impair the patient's ability to participate.
* Legal incapacity or limited legal capacity.
* Unable to understand or give signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol. Examples include certain psychiatric conditions.
* Patients who have received a live or live-attenuated vaccine within 30 days before the first dose of study drug. Administration of killed vaccines is allowed.
* Pregnant or lactating.
* Severe hypersensitivity (≥ Grade 3) to study drugs and/or any of their excipients.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Dragonfly Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, United States
University of California Irvine Medical Center
Orange, California, United States
University of California San Diego Moores Cancer Center
San Diego, California, United States
Sarcoma Oncology Center
Santa Monica, California, United States
Tampa General Hospital
Tampa, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
NYU Langone Health
New York, New York, United States
Lifespan - Rhode Island Hospital
Providence, Rhode Island, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Cancer Research SA (CRSA)
Adelaide, South Australia, Australia
Peninsula and South East Oncology Medical (PASO)
Frankston, Victoria, Australia
Institut Bergonié
Bordeaux, , France
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, , France
Centre Georges François Leclerc
Dijon, , France
CHU de Marseille - Hôpital de la Timone
Marseille, , France
Institut Paoli-Calmettes
Marseille, , France
Institut Curie
Paris, , France
Hôpital Lyon-Sud
Pierre-Bénite, , France
Centre Hospitalier Universitaire de Poitiers
Poitiers, , France
Institut de Cancérologie de l'Ouest - Saint-Herblain - Site René Gauducheau
Saint-Herblain, , France
Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Navid Hafez, M.D., MPH
Role: primary
Jennifer Valerin, M.D., PhD
Role: primary
Gregory Daniels, M.D., PhD
Role: primary
Sant Chawla, M.D.
Role: primary
Mayer Fishman, M.D.
Role: primary
Ahmad Tarhini, M.D., PhD
Role: primary
Maya Dimitrova, M.D.
Role: primary
Benedito Carneiro, M.D.
Role: primary
Meredith McKean, M.D.
Role: primary
Sarwan Bishnoi, MBBS, MD, FRACP
Role: primary
Vinod Ganju, MBBS, FRACP
Role: primary
Antoine Italiano, M.D., PhD
Role: primary
Antoine Italiano, M.D., PhD
Role: primary
François Ghiringhelli, M.D., PhD
Role: primary
Caroline Gaudy, M.D., PhD
Role: primary
Cecile Vicier, M.D., PhD
Role: primary
Emanuela Romano, M.D., PhD
Role: primary
Benoit You, M.D., PhD
Role: primary
Nicolas Isambert, M.D.
Role: primary
Judith Raimbourg, M.D.
Role: primary
Iphigenie Korakis, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KEYNOTE-G13
Identifier Type: OTHER
Identifier Source: secondary_id
MK-3475-G13
Identifier Type: OTHER
Identifier Source: secondary_id
DF6215-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.